PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study (PATSUD)

This randomised, controlled trial (n=86) will assess the safety, feasibility, and efficacy of PEX010 (psilocybin) for the treatment of stimulant use disorder in adults. Participants will receive either a 25 mg dose of PEX010 or a 1 mg active placebo in conjunction with cognitive behavioural therapy.

The study involves two preparation sessions, one PEX010 dosing session, one integration session, and seven follow-up visits. The primary outcome measure is the reduction in stimulant use, assessed via the Timeline Followback method and urine drug tests over three months. Secondary outcomes include monitoring adverse events and serious adverse events.

The trial, sponsored by Filament Health Corp., is expected to start in January 2025 and complete in July 2028.

Topic Addiction Safety
Compound Psilocybin Placebo
Country Canada
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University of British Columbia


Filament Health
Filament Health is a global extraction and drug discovery company. The company have a deep natural psychedelics IP portfolio and are led by an accomplished botanical extraction management team.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.